341 related articles for article (PubMed ID: 31753111)
21. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
22. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
Acosta AM; Kadkol SS
Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
24. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.
Cheng L; Lopez-Beltran A; Massari F; MacLennan GT; Montironi R
Mod Pathol; 2018 Jan; 31(1):24-38. PubMed ID: 29148538
[TBL] [Abstract][Full Text] [Related]
25. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
26. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
27. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Ilieva KM; Correa I; Josephs DH; Karagiannis P; Egbuniwe IU; Cafferkey MJ; Spicer JF; Harries M; Nestle FO; Lacy KE; Karagiannis SN
Mol Cancer Ther; 2014 Dec; 13(12):2769-83. PubMed ID: 25385327
[TBL] [Abstract][Full Text] [Related]
28. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
29. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
31. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A; Egyhazi S; Ringborg U; Hansson J
Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
[TBL] [Abstract][Full Text] [Related]
32. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
33. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
34. [Modern methods of molecular targeted therapy for disseminated melanoma].
Novik AV; Protsenkol SA; Semenova AI; Latipova DKh; A S Zhabina ; Akhaeva ZY
Vopr Onkol; 2015; 61(2):297-302. PubMed ID: 26087614
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
36. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
37. BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.
Godoy-Gijón E; Yuste-Chaves M; Santos-Briz Á
Actas Dermosifiliogr; 2017 Dec; 108(10):894-901. PubMed ID: 28711165
[TBL] [Abstract][Full Text] [Related]
38. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
Fedorenko IV; Gibney GT; Smalley KS
Oncogene; 2013 Jun; 32(25):3009-18. PubMed ID: 23069660
[TBL] [Abstract][Full Text] [Related]
39. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
